Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

The opinions of community hematologist/oncologists were sought regarding minimal residual disease (MRD) testing in multiple myeloma patients, examining the factors influencing its use, barriers to its adoption, and how results impact treatment decisions. A survey of 22 practitioners revealed that while most were comfortable with MRD testing, actual usage was low. The primary motivation for testing was monitoring remission status, but logistical challenges in sending samples were the main obstacle. The study concludes that reducing these barriers and providing more clinical data are crucial to developing guidelines and improving the integration of MRD testing into practice.